Immunome IMNM Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $582.69M+126% | $653.48M+356% | $272.64M+75.3% | $143.88M-13.0% | $257.61M-4.5% | ||
| $210K+110% | $210K+110% | $210K+110% | $210K+110% | $100K0.0% | ||
| $11.62M+100% | $7.3M+80.7% | $7.29M+86.3% | $9.4M+58.4% | $5.81M+60.4% | ||
| $594.31M+83.9% | $660.78M+199% | $279.92M+14.7% | $277.43M-2.4% | $323.13M+3.1% | ||
| $17.08M+55.9% | $14.64M+44.7% | $11.56M+61.2% | $11.03M+80.9% | $10.95M+155% | ||
| $2.83M-32.1% | $2.98M-30.4% | $3.13M+30.9% | $3.27M+29.6% | $4.16M+186% | ||
| $5.36M+23.4% | $4.59M+4.0% | $4.56M+42.4% | $4.35M+35.6% | $4.35M+665% | ||
| $619.79M+80.9% | $683.19M+184% | $299.38M+16.5% | $296.29M0.0% | $342.69M+7.2% | ||
| $5.53M-39.4% | $3.34M-76.5% | $6.15M+74.7% | $4.66M-33.9% | $9.13M+27.1% | ||
| $21.88M+23.9% | $41.65M+25.5% | $25.3M-3.9% | $18.22M-10.1% | $17.66M+62.8% | ||
| —— | $0-100% | $0-100% | $0-100% | $4.02M-68.5% | ||
| $27.41M-11.0% | $44.99M-17.2% | $31.45M-20.4% | $22.88M-42.7% | $30.8M+0.1% | ||
| $3.69M-22.6% | $3.86M-19.2% | $4.01M+62.9% | $4.14M+67.2% | $4.77M+296% | ||
| $3.69M-22.6% | $3.86M-20.2% | $4.01M+47.5% | $4.14M+49.4% | $4.77M— | ||
| $31.11M-12.5% | $48.85M-17.3% | $35.46M-15.6% | $27.02M-36.2% | $35.57M+4.1% | ||
| $11K+22.2% | $11K+83.3% | $9K+50.0% | $9K+50.0% | $9K+50.0% | ||
| $1.37B+58.5% | $1.36B+95.5% | $922.17M+41.8% | $870.09M+35.5% | $864.53M+35.5% | ||
| -$782M-40.3% | -$728.16M-41.2% | -$658.26M-51.1% | -$600.81M-54.7% | -$557.41M-58.2% | ||
| —— | $0-100% | $0-100% | -$24K-1,300% | -$3K-175% | ||
| $588.69M+91.7% | $634.34M+250% | $263.92M+22.8% | $269.27M+6.1% | $307.13M+7.5% | ||
| $619.79M+80.9% | $683.19M+184% | $299.38M+16.5% | $296.29M0.0% | $342.69M+7.2% | ||
| $5.36M+23.4% | $4.59M+4.0% | $4.56M+42.4% | $4.35M+35.6% | $4.35M+665% | ||
| $2.83M-32.1% | $2.98M-30.4% | $3.13M+30.9% | $3.27M+29.6% | $4.16M+186% | ||
| $2.83M-32.1% | $2.98M-30.4% | $3.13M+30.9% | $3.27M+29.6% | $4.16M+186% | ||
| $5.36M+23.4% | $4.59M+4.0% | $4.56M+42.4% | $4.35M+35.6% | $4.35M+665% | ||
| $2.83M-32.1% | $2.98M-30.4% | $3.13M+30.9% | $3.27M+29.6% | $4.16M+186% | ||
| $5.36M+23.4% | $4.59M+4.0% | $4.56M+42.4% | $4.35M+35.6% | $4.35M+665% | ||
| $21.88M+23.9% | $41.65M+25.5% | $25.3M-3.9% | $18.22M-10.1% | $17.66M+62.8% | ||
| $3.69M-22.6% | $3.86M-20.2% | $4.01M+47.5% | $4.14M+49.4% | $4.77M+296% | ||
| $11K+22.2% | $11K+83.3% | $9K+50.0% | $9K+50.0% | $9K+50.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Immunome cover its short-term obligations?
- Its current ratio is 21.68 — current assets exceed current liabilities.
- Where does Immunome's balance sheet data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.